We are using technical cookies that are necessary for page to work correctly.

Y-shaped Adapter-ligated MAture TRNA sequencing

Details for Y-shaped Adapter-ligated MAture TRNA sequencing
Full nameY-shaped Adapter-ligated MAture TRNA sequencing
SummaryEmploying the efficient and specific ligation of Y-shaped adapter to mature tRNAs using T4 RNA Ligase 2
Key findingsMature tRNA expression varies between breast cancer cell lines
Sequencing strategyRNA-seq
Raw datahttps://www.ncbi.nlm.nih.gov/sra/?term=SRP096584
Experimental protocolTotal RNA was extracted from cultured cells using TRIsure (Bioline) according to the manufacturer's protocol. Total RNAs were incubated at 37°C for 40 min in 20 mM Tris-HCl (pH 9.0) to remove amino acids from mature tRNAs (deacylation treatment), followed by ethanol precipitation. A DNA adapter containing Illumina 3΄-adapter sequences (Y-3΄-AD) and four different DNA/RNA hybrid adapters containing Illumina 5΄-adapter sequences and a 3΄-terminal A (Y-5΄-AD-A), G (Y-5΄-AD-G), C (Y-5΄-AD-C) or U (Y-5΄-AD-U) were synthesized by Integrated DNA Technologies. The adapter sequences were as follows (capital and small letters designate DNA and RNA, respectively): Y-3΄-AD, 5΄-5phos/GTATCCAGTTGGAATTCTCGGGTGCCAAGG/3ddC-3΄; Y-5΄-AD-A, 5΄-GTTCAGAGTTCTACAGTCCGACGATCACTGGATACTGga-3΄; Y-5΄-AD-G, 5΄-GTTCAGAGTTCTACAGTCCGACGATCACTGGATACTGgg-3΄; Y-5΄-AD-C, 5΄-GTTCAGAGTTCTACAGTCCGACGATCACTGGATACTGgc-3΄; and Y-5΄-AD-U, 5΄-GTTCAGAGTTCTACAGTCCGACGATCACTGGATACTGgu-3΄. The Y-shaped adapters comprising Y-3΄-AD/Y-5΄-AD-A, Y-3΄-AD/Y-5΄-AD-G, Y-3΄-AD/Y-5΄-AD-C and Y-3΄-AD/Y-5΄-AD-U are expected to hybridize mature tRNAs with discriminator bases of U, C, G and A, respectively. Four different Y-5΄-AD adapters (10 pmol each) and 40 pmol of the Y-3΄-AD adapter were incubated with 1 μg of deacylated total RNA in a 9-μl reaction volume at 90°C for 2 min. After adding 1 μl of 10× annealing buffer containing 50 mM Tris-HCl (pH 8.0), 5 mM ethylenediaminetetraacetic acid and 100 mM MgCl2, the 10-μl mixture was subjected to annealing at 37°C for 15 min. To ligate the annealed adapter to mature tRNAs, 10 μl of 1× reaction buffer containing 1 unit of Rnl2 (New England Biolabs) was added to the mixture. The entire mixture (20 μl) was incubated at 37°C for 1 h, followed by overnight incubation at 4°C. cDNA amplification was performed using the TruSeq Small RNA Sample Preparation Kit (Illumina) according to the manufacturer's protocol. Briefly, 6 μl of ligated RNA and 1 μl of RTP primer were incubated at 70°C for 2 min and then placed on ice. Reverse transcription was subsequently performed by adding 5.5 μl of a RT reaction mixture comprising 2 μl of 5× First Strand Buffer, 0.5 μl of 12.5 mM each dNTP, 1 μl of 100 mM dithiothreitol, 1 μl of RNase inhibitor and 1 μl of SuperScript III Reverse Transcriptase (Life Technologies), followed by incubation at 55°C for 60 min. The resultant cDNAs were amplified by polymerase chain reaction (PCR) (11 cycles) using a PCR enzyme mix (PML) and primers included in the Illumina kit. PCR products were developed using 8% native polyacrylamide gel electrophoresis (PAGE), and mature tRNA amplified regions were gel-purified. To confirm the amplified cDNA sequences, purified cDNAs were cloned using StrataClone Blunt PCR Cloning Kit (Agilent Technologies). The cDNAs were further sequenced (100 nt single-read) on an Illumina HiSeq 2500.
Analysis protocolSHRiMP2 was used to map the reads to a set of 632 tRNA-reference genes (listed in gtRNAdb). Non-unique mappings with a 10% mismatch rate were allowed, penalizing each mismatch and gap extension equally. Reads were also mapped to the full GRCh37 assembly and excluded the read if it mapped equally or better to non-tRNA space when compared with the tRNA-reference gene mapping. Only reads that were 60–87 nt were kept.
Organism/cell lineH. sapiens (BT-474, SK-BR-3, BT-20, MCF-7 breast cancer cell lines)
Approximate experimental time2-3 days
Starting RNA amount1 µg total RNA
tRNA expression++
Base modifications-
Charging status-
tRNA processing and fragmentation-
Citationhttps://doi.org/10.1093/nar/gkx005